# Andersen PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/andersen

> Andersen, sponsored by NOMAD POWER SOLUTIONS, INC. (NMAD): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | andersen |
| Codes |  |
| Sponsor | NOMAD POWER SOLUTIONS, INC. (NMAD) https://sec-api.dev/companies/nmad/catalysts |
| Indications | [ovarian clear cell carcinoma](https://sec-api.dev/indications/ovarian-clear-cell-carcinoma) |
| Modality | antisense |
| FDA designations | none disclosed |

## Timeline

### May 15, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1/2. Indication: ovarian clear cell carcinoma.
- First seen 2024-11-12, last confirmed 2026-05-14.
- SEC Form 10-Q (accession 0001493152-26-023150): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000149315226023150/form10-q.htm
- SEC Form 10-K (accession 0001493152-26-014052): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000149315226014052/form10-k.htm
- SEC Form 10-Q (accession 0001493152-25-021941): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000149315225021941/form10-q.htm
- SEC Form 10-Q (accession 0001641172-25-022517): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000164117225022517/form10q.htm
- SEC Form 10-K (accession 0001641172-25-000208): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000164117225000208/form10-k.htm
- SEC Form 10-Q (accession 0001493152-24-044810): "On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 ("PD-1") blocking antibody of GSK plc ("GSK"), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma ("OCCC")." https://www.sec.gov/Archives/edgar/data/1335105/000149315224044810/form10-q.htm

## Same indication

- [LB-100](https://sec-api.dev/pdufa/lb-100) (NMAD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/andersen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Andersen PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/andersen

```bibtex
@misc{secapidev_pdufa_andersen_20261116,
  title        = {Andersen PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/andersen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_andersen_20261116","title":"Andersen PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/andersen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
